Promise and pitfalls of animal models of schizophrenia

Current Psychiatry Reports

Volumn 12, Issue 4, 2010, Pages 327-334

  Feifel, David ^a   Shilling, Paul D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Animal models; Antipsychotics; Psychosis; Schizophrenia

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT;

ALZHEIMER DISEASE; CATATONIC SCHIZOPHRENIA; CLINICAL FEATURE; CONSTRUCT VALIDITY; CONTROL STRATEGY; DELUSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ACTIVITY; DISEASE MARKER; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; GENETIC IDENTIFICATION; GENETIC TRAIT; HALLUCINATION; HEBEPHRENIA; HERITABILITY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; NEGATIVE SYNDROME; NEUROPSYCHOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPIC VARIATION; POSITIVE SYNDROME; PREDICTIVE VALIDITY; PSYCHOLOGICAL MODEL; REVIEW; SCHIZOPHRENIA; SPEECH DISORDER; SYMPTOM; VALIDATION PROCESS; ANIMAL; TRANSLATIONAL RESEARCH;

ANIMALS; DISEASE MODELS, ANIMAL; SCHIZOPHRENIA; TRANSLATIONAL RESEARCH; TRANSLATIONAL MEDICAL RESEARCH;

EID: 77956393304     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-010-0122-x     Document Type: Review

References (45)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, edn 4 (text revision). Washington, DC: American Psychiatric Association; 2000.
2. Mouri A, Noda Y, Enomoto T, Nabeshima T: Phencyclidine animal models of schizophrenia: Approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int 2007, 51:173-184.
3. Holmes PV: Rodent models of depression: Reexamining validity without anthropomorphic inference. Crit Rev Neurobiol 2003, 15:143-174.
4. Geyer MA, Markou A: The role of preclinical models in the development of psychotropic drugs. In Neuropsychopharmacology: The Fifth Generation of Progress. Edited by Davis KL, Charney D, Coyle JT, Nemeroff CB. Washington, DC: American College of Neuropsychopharmacology; 2002:445-455
5. van der Staay FJ, Arndt SS, Nordquist RE: Evaluation of animal models of neurobehavioral disorders. Behav Brain Funct 2009, 5:11. This article addresses systematic approaches to the development and evaluation of animal models used to investigate neuropsychiatric disorders.
6. da Conceicao FS, Ngo-Abdalla S, Houzel JC, Rehen SK: Murine model for Parkinson's disease: From 6-OH dopamine lesion to behavioral test. J Vis Exp 2010, 35:1376.
7. Keshavan MS, Tandon R, Boutros NN, Nasrallah HA: Schizophrenia, "just the facts": What we know in 2008. Part 3: Neurobiology. Schizophr Res 2008, 106:89-107. This article describes potential intermediate phenotypes that may reflect "diverse pathological pathways from the phenome to genome" that could facilitate the discovery of novel etiologies and drug targets for schizophrenia.
8. Tandon R, Keshavan MS, Nasrallah HA: Schizophrenia, "just the facts": What we know in 2008. Part 1: Overview. Schizophr Res 2008, 100:4-19. A total of 77 major findings in schizophrenia research are described and organized in terms of their relevance to etiology, pathophysiology, symptomatology, and treatment.
9. Tamminga CA, Holcomb HH: Phenotype of schizophrenia: A review and formulation. Mol Psychiatry 2005, 10:27-39.
10. Seeman MV: Pharmacologic features and effects of neuroleptics. Can Med Assoc J 1981, 125:821-826.
11. Braff DL, Freedman R, Schork NJ, Gottesman II: Deconstructing schizophrenia: An overview of the use of endophenotypes in order to understand a complex disorder. Schizophr Bull 2007, 33:21-32. This article summarizes progress in the use of endophenotypes in the identification of the genetics and potential drug targets for schizophrenia.
12. Gottesman, II, Gould TD: The endophenotype concept in psychiatry: Etymology and strategic intentions. Am J Psychiatry 2003, 160:636-645.
13. Turetsky BI, Calkins ME, Light GA, et al.: Neurophysiological endophenotypes of schizophrenia: The viability of selected candidate measures. Schizophr Bull 2007, 33:69-94.
14. Braff DL, Geyer MA: Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 1990, 47:181-188.
15. Swerdlow NR, Braff DL, Taaid N, Geyer MA: Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994, 51:139-154.
16. Marder SR, Fenton W: Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 2004, 72:5-9.
17. Nuechterlein KH, Barch DM, Gold JM, et al.: Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004, 72:29-39.
18. Nuechterlein KH, Green MF, Kern RS, et al.: The MATRICS Consensus Cognitive Battery, part 1: Test selection, reliability, and validity. Am J Psychiatry 2008, 165:203-213.
19. GeyerMA, MoghaddamB:Animalmodels relevant to schizophrenia disorders. In Neuropsychopharmacology: The Fifth Generation of Progress. Edited by Davis KL, Charney D, Coyle JT, Nemeroff C. Washington, DC: American College of Neuropsychopharmacology; 2002:689-701.
20. Tordjman S, Drapier D, Bonnot O, et al.: Animal models relevant to schizophrenia and autism: Validity and limitations. Behav Genet 2007, 37:61-78.
21. Nuechterlein KH, Robbins TW, Einat H: Distinguishing separable domains of cognition in human and animal studies: What separations are optimal for targeting interventions? A summary of recommendations from breakout group 2 at the measurement and treatment research to improve cognition in schizophrenia new approaches conference. Schizophr Bull 2005, 31:870-874.
22. Young JW, Powell SB, Risbrough V, et al.: Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 2009, 122:150-202.
23. Tamminga CA, Buchanan RW, Gold JM: The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol 1998, 13(Suppl 3):S21-S26.
24. Meltzer HY: Cognitive factors in schizophrenia: Causes, impact, and treatment. CNS Spectr 2004, 9:15-24.
25. Swerdlow NR, Weber M, Qu Y, et al.: Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl) 2008, 199:331-388. This article elucidates the strengths and weaknesses of PPI as a translational model for schizophrenia research.
26. Gandy S: The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest 2005, 115:1121-1129.
27. Minassian A, Henry BL, Geyer MA, et al.: The quantitative assessment of motor activity in mania and schizophrenia. J Affect Disord 2010, 120:200-206.
28. Foussias G, Remington G: Antipsychotics and schizophrenia: From efficacy and effectiveness to clinical decision-making. Can J Psychiatry 2010, 55:117-125.
29. Lambert TJ: The medical care of people with psychosis. Med J Aust 2009, 190:171-172.
30. Van den Buuse M, Garner B, Koch M: Neurodevelopmental animal models of schizophrenia: Effects on prepulse inhibition. Curr Mol Med 2003, 3:459-471.
31. Fone KC, Porkess MV: Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders. Neurosci Biobehav Rev 2008, 32:1087-1102.
32. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR: Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology (Berl) 2001, 156:117-154.
33. Weiss IC, Feldon J, Domeney AM: Isolation rearing-induced disruption of prepulse inhibition: Further evidence for fragility of the response. Behav Pharmacol 1999, 10:139-149.
34. Tseng KY, Chambers RA, Lipska BK: The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav Brain Res 2009, 204:295-305. This article reviews the advantages and limitations of the neonatal ventral hippocampal model of schizophrenia, the most thoroughly characterized developmentally based model for this disorder.
35. Le Pen G, Moreau JL: Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: Reversal by clozapine, olanzapine and risperidone but not by haloperidol. Neuropsychopharmacology 2002, 27:1-11.
36. Rueter LE, Ballard ME, Gallagher KB, et al.: Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia. Psychopharmacology (Berl) 2004, 176:312-319.
37. Levin ED, Christopher NC: Effects of clozapine onmemory function in the rat neonatal hippocampal lesion model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:223-229.
38. Feifel D, Priebe K: Vasopressin-deficient rats exhibit sensorimotor gating deficits that are reversed by subchronic haloperidol. Biol Psychiatry 2001, 50:425-433.
39. Laycock JF, Gartside IB, Chapman JT: A comparison of the learning abilities of Brattleboro rats with hereditary diabetes insipidus and Long-Evans rats using positively reinforced operant conditioning. Prog Brain Res 1983, 60:183-187.
40. Feifel D, Mexal S, Melendez G, et al.: The Brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog. Neuropsychopharmacology 2009, 34:2011-2018.
41. Feifel D, Melendez G, Priebe K, Shilling PD: The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats. Behav Brain Res 2007, 181:278-286.
42. Feifel D, Melendez G, Shilling PD: Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: A potential predictive model for novel antipsychotic effects. Neuropsychopharmacology 2004, 29:731-738.
43. Feifel D, Priebe K: The effects of cross-fostering on inherent sensorimotor gating deficits exhibited by Brattleboro rats. J Gen Psychol 2007, 134:173-182.
44. Shilling PD, Kinkead B, Murray T, et al.: Upregulation of striatal dopamine-2 receptors in Brattleboro rats with prepulse inhibition deficits. Biol Psychiatry 2006, 60:1278-1281.
45. Linkowski P, Geenen V, Kerkhofs M, et al.: Cerebrospinal fluid neurophysins in affective illness and in schizophrenia. Eur Arch Psychiatry Neurol Sci 1984, 234:162-165.